April 30, 2019
Cannvas Secures Revenue Agreement with Medical Marihuana Patient Relief
Cannvas.Me to Provide Seamless Referrals to MM Patient Relief
TORONTO, April 30, 2019 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC) (Frankfurt: 3CM) (OTCPK: CANVF), a leading digital cannabis education and analytics company, is pleased to announce the signing of a revenue sharing agreement with Medical Marihuana Patient Relief Inc. (“MM Patient Relief”), a private locally-owned producer based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains. Cannvas and MM Patient Relief are jointly deploying technologies to increase value-added services offered between company platforms while driving customer integration.
“We are proud to have developed the leading digital cannabis education resource for Canadians curious about the potential benefits of cannabis consumption, and this partnership with Medical Marihuana Patient Relief adds value to each of our communities,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech. “Providing MM Patient Relief’s community with better access to cannabis education while Cannvas.Me users gain an option to follow up with MM Patient Relief for their therapeutic cannabis needs, if they so choose, ensures a mutually beneficial scenario.”
Cannvas expects to leverage its data analysis capabilities and work with MM Patient Relief to generate revenue through tracking the number of Cannvas.Me users who choose MM Patient Relief as their primary cannabis provider, and can track purchases made throughout the lifetime of a patient.
Established in 2014, Medical Marihuana Patient Relief Inc. is currently in the final stages of review and approval under Health Canada’s MMPR/ACMPR (Access to Cannabis for Medical Purposes Regulations).
About Medical Marihuana Patient Relief
Established in 2014, Medical Marihuana Patient Relief Inc. (MM Patient Relief) is a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains for pain, arthritis, and cancer. Using advanced cultivation methods that maximize production and have increased the number of yearly crop cycles from four to six, MM Patient Relief is in the final stage of Health Canada MMPR / ACMPR (Access to Cannabis for Medical Purposes Regulation) approval and finalizing construction of its state-of-the-art stand-alone facility. For more information: www.mmpatientrelief.com
About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.